Cargando…
Immunotherapy for recurrent hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is presented frequently in late stages that are not amenable for curative treatment. Even for patients who can undergo resection for curative treatment of HCC, up to 50% recur. For patients who were not exposed to systemic therapy prior to recurrence, recurrence freque...
Autores principales: | Bhatt, Ahan, Wu, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134420/ https://www.ncbi.nlm.nih.gov/pubmed/37124885 http://dx.doi.org/10.3748/wjg.v29.i15.2261 |
Ejemplares similares
-
Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018) -
Targets of immunotherapy for hepatocellular carcinoma: An update
por: Rai, Vikrant, et al.
Publicado: (2022) -
Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
por: Chen, Pu, et al.
Publicado: (2021) -
Ablative strategies for recurrent hepatocellular carcinoma
por: Wang, Lin, et al.
Publicado: (2023) -
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
por: Mandlik, Deepa S, et al.
Publicado: (2023)